Examples
Worked examples
- Is an instance
A biologics manufacturer running commercial production of an approved monoclonal antibody statistically trends bioreactor yield, purity, and potency data across every batch under its CPV program; a gradual downward drift in potency across several consecutive lots -- still individually within specification -- triggers an investigation rather than waiting for an outright specification failure.
- Is an instance
A contract manufacturing organization producing a late-phase investigational drug substance documents in-process parameter data (pH, temperature, mixing time) at each batch, then reduces sampling to a routine, statistically justified frequency once enough batches exist to characterize normal process variability -- a Stage 3 practice applied as the product approaches commercial supply.
Counter-examples
Looks similar, but isn't
- Not an instance
A single successful Process Performance Qualification (PPQ) run -- three consecutive conforming validation lots signed off and filed -- is not CPV. That is Stage 2 (Process Qualification): a point-in-time demonstration that the process is capable, not the ongoing Stage 3 program that follows it.
Editorial commentary
Continued Process Verification (CPV) is Stage 3 of the FDA’s three-stage lifecycle approach to process validation, set out in the FDA’s January 2011 guidance, Process Validation: General Principles and Practices (issued by CDER in cooperation with CBER, ORA, and CVM, superseding the agency’s 1987 process-validation guideline). CPV is the ongoing collection and statistical evaluation of process and product data during routine commercial production, used to confirm that a manufacturing process continues to operate in a validated “state of control” after it has moved past initial qualification.
Where CPV Sits in the Three-Stage Lifecycle
The 2011 guidance replaced the older “three consecutive validation lots” standard with a lifecycle model that treats validation as continuous, not a one-time event completed before launch:
- Stage 1 — Process Design. The commercial manufacturing process is defined based on knowledge gained during development and scale-up, using risk assessment, design of experiments, and an understanding of the quality target product profile. This stage answers “why does this process work,” not just “does it work.”
- Stage 2 — Process Qualification. The facility, utilities, and equipment are qualified (installation qualification/operational qualification), and the process is evaluated at commercial scale through a written Process Performance Qualification (PPQ) protocol with a statistically justified sampling plan. Stage 2 confirms the process is capable of reproducible commercial manufacturing.
- Stage 3 — Continued Process Verification. Once a process has passed Stage 2 and moves into routine commercial production, CPV provides ongoing assurance — through continued data collection and trending — that the process remains in that validated state for the life of the product.
What CPV Actually Requires
The 2011 guidance and 21 CFR 211.180(e) (the current-good-manufacturing-practice requirement for an ongoing program of stability and process review) together describe CPV as a sustained program, not a single review event. In practice this means:
- Collecting data on in-process parameters and critical quality attributes at each production batch or lot.
- Statistically trending that data over time — not just checking pass/fail against a specification, but watching for drift, shifts, or increased variability that a single-batch view would miss.
- Reviewing performance against the process understanding established in Stage 1 and the acceptance criteria confirmed in Stage 2.
- Adjusting monitoring intensity over time: sampling typically starts at the level established during Stage 2 qualification and is reduced to a statistically justified routine level only once enough data exists to characterize normal process variability.
- Feeding findings back into the quality system — unexpected variation, deviations, or trending failures trigger investigation and, where warranted, corrective action or a return to a more qualification-like level of scrutiny.
The goal is the same “state of control” language used throughout the guidance: quality attributes are consistently within their established range, and the process is behaving predictably enough that its outputs can be trusted without exhaustive end-product testing of every lot.
Why It Matters for Research Institutions
Most CASRAI readers are not running a commercial manufacturing line, but CPV becomes directly relevant the moment a research institution’s product — a biologic, a cell or gene therapy, an active pharmaceutical ingredient, or a device — is manufactured under Good Manufacturing Practice (GMP) for use in a clinical trial or after approval. GMP defines what must be controlled about the production environment; the three-stage process validation lifecycle, and CPV specifically, defines how an institution proves, on an ongoing basis, that its process is actually delivering consistent quality — the evidentiary backbone an FDA inspector, IND/BLA reviewer, or licensing partner will expect to see documented.
For investigational products specifically, CPV expectations scale with development phase: an early-phase investigational medicinal product (IMP) manufactured for a first-in-human trial will not have the same volume of commercial-production history a Stage 3 program is built on, but the same underlying discipline — documented data collection, trend review, and a defined response to out-of-trend results — is expected to mature as a product advances toward late-phase trials and eventual commercial manufacturing. See Clinical Trial Supply Management for how IMP manufacturing, distribution, and accountability fit into the broader trial-supply chain that CPV data ultimately supports.
Worked Examples
- A biologics manufacturer running commercial production of an approved monoclonal antibody maintains a CPV program that statistically trends bioreactor yield, purity, and potency data across every batch; a gradual downward drift in potency across several consecutive lots — still individually within specification — triggers an investigation under the CPV program rather than waiting for an outright specification failure.
- A contract manufacturing organization (CMO) producing a late-phase investigational drug substance under a sponsor’s GMP oversight documents in-process parameter data (pH, temperature, mixing time) at each qualification-stage sampling frequency, then reduces sampling to a routine level once enough batches have been produced to establish a statistically supported baseline — a Stage 3 practice applied to a still-investigational product as it approaches late-phase and eventual commercial supply.
Counter-Example
A single successful Process Performance Qualification (PPQ) run — three consecutive conforming validation lots signed off and filed — is not Continued Process Verification. That activity is Stage 2 (Process Qualification): a point-in-time demonstration that the process is capable. CPV is the ongoing Stage 3 program that follows PPQ and continues for as long as the product is in commercial production; a facility that treats its three validation lots as “done” and stops routine trend review afterward has completed Stage 2 but has not implemented Stage 3, and would not meet the 2011 guidance’s lifecycle expectations or 21 CFR 211.180(e)’s ongoing-review requirement.
Related Terms
Machine-readable encodings
Use in your systems
<role vocab="credit"
vocab-identifier="https://casrai.org/dictionary/"
vocab-term="Continued Process Verification (CPV)"
vocab-term-identifier="https://casrai.org/dictionary/term/continued-process-verification-cpv" />{
"@context": "https://schema.org",
"@type": "DefinedTerm",
"@id": "https://casrai.org/dictionary/term/continued-process-verification-cpv",
"name": "Continued Process Verification (CPV)",
"identifier": "https://casrai.org/dictionary/term/continued-process-verification-cpv",
"description": "Continued Process Verification (CPV) is Stage 3 of the FDA's three-stage process validation lifecycle, set out in the FDA's January 2011 guidance \"Process Validation: General Principles and Practices.\" It is an ongoing program -- required under 21 CFR 211.180(e) -- of collecting and statistically trending process and product data during routine commercial production to confirm the manufacturing process remains in a validated \"state of control\" after Stage 1 (Process Design) established the process and Stage 2 (Process Qualification) demonstrated it was capable of reproducible commercial manufacturing. A single Process Performance Qualification run is Stage 2, not CPV -- CPV is the continuing program that follows it for the life of the product.",
"inDefinedTermSet": "https://casrai.org/dictionary/domain/compliance-regulatory#set",
"url": "https://casrai.org/dictionary/term/continued-process-verification-cpv",
"sameAs": [],
"license": "https://creativecommons.org/licenses/by/4.0/",
"publisher": {
"@id": "https://casrai.org/#organization"
},
"dateModified": "2026-07-17T06:38:48",
"inLanguage": "en"
}
